- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
May 23rd, 2005
Jack Uldrich: In February, pSivida (Nasdaq: PSDV), an Australian-based company specializing in biomedical applications of nanotechnology, began trading on the Nasdaq as an American Depositary Receipt (ADR). In its first three months on Wall Street, it promptly fell from a high of $10 a share to just over $4.
Since that time, however, pSivida's stock has risen by more than 65%. It currently trades at around $7.
Will it continue to rise? I believe so, and I base that answer on three recent developments.
|Related News Press|
Animal study shows flexible, dissolvable silicon device promising for brain monitoring: Other applications include post-operative observation for vascular, cardiac, and orthopaedic procedures, finds Penn study May 5th, 2016
Aspen Aerogels to Present at the 28th Annual ROTH Conference March 14th, 2016
Arrowhead to Present at Upcoming March Conferences March 1st, 2016
Russia’s Nano-enabled Products Market to Witness Massive Growth February 8th, 2011
Adept Technology Announces Orders for Over $600K from Chinese Partner January 18th, 2011
Nanostart-held ItN Nanovation Receives Major Follow-on Order in Saudi Arabia November 29th, 2010
Homegrown Companies Developing Batteries for Clean Energy Storage November 2nd, 2010
Arrowhead to Webcast Fiscal 2015 Year End Results December 7th, 2015
Haydale Announce Year End Results November 3rd, 2015